Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-na ïve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYNOTE-01A)
Condition: Carcinoma, Non-Small-Cell Lung Interventions: Biological: Pembrolizumab; Drug: Carboplatin; Drug: Paclitaxel; Drug: Pemetrexed; Biological: MK-7684 Sponsor: Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alimta | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Research | Study